阿斯利康(AZN.US)投资Summit(SMMT.US)获小摩与花旗看好:癌症药物策略迎验证

智通财经
Sep 29
【阿斯利康(AZN.US)投资Summit(SMMT.US)获小摩与花旗看好:癌症药物策略迎验证】智通财经APP获悉,阿斯利康(AZN.US)宣布投资美国生物技术公司 Summit Therapeutics(SMMT.US)、就一款新的抗癌药物展开合作后,阿斯利康周二盘前上涨约2%,SMMT 涨幅扩大,上涨约23%。摩根大通与花旗的分析师对这笔交易表示欢迎,称其与阿斯利康的癌症战略相一致。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10